Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NEPH NYSE:NSPR NASDAQ:SURG NASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNEPHNephros$3.37-5.6%$3.35$2.66▼$6.42$38.76M1.4910,735 shs3,776 shsNSPRInspireMD$0.68-2.5%$0.95$0.63▼$2.93$31.97M0.74175,541 shs63,692 shsSURGSurgePays$0.41+14.9%$0.51$0.34▼$3.45$9.07M0.39218,171 shs52.44 million shsTELATELA Bio$0.72-4.0%$0.86$0.50▼$2.20$33.58M1.34116,791 shs35,881 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNEPHNephros-5.60%+0.60%-8.67%+17.42%-16.38%NSPRInspireMD-2.51%-2.51%-31.06%-55.68%-69.39%SURGSurgePays+14.93%+5.84%-30.36%-42.57%-86.44%TELATELA Bio-4.00%-4.01%-20.00%+20.54%-63.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNEPHNephros$3.37-5.6%$3.35$2.66▼$6.42$38.76M1.4910,735 shs3,776 shsNSPRInspireMD$0.68-2.5%$0.95$0.63▼$2.93$31.97M0.74175,541 shs63,692 shsSURGSurgePays$0.41+14.9%$0.51$0.34▼$3.45$9.07M0.39218,171 shs52.44 million shsTELATELA Bio$0.72-4.0%$0.86$0.50▼$2.20$33.58M1.34116,791 shs35,881 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNEPHNephros-5.60%+0.60%-8.67%+17.42%-16.38%NSPRInspireMD-2.51%-2.51%-31.06%-55.68%-69.39%SURGSurgePays+14.93%+5.84%-30.36%-42.57%-86.44%TELATELA Bio-4.00%-4.01%-20.00%+20.54%-63.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNEPHNephros 2.50Moderate Buy$6.0078.04% UpsideNSPRInspireMD 3.00Buy$4.50559.34% UpsideSURGSurgePays 1.67Reduce$3.50743.58% UpsideTELATELA Bio 2.40Hold$2.20205.56% UpsideCurrent Analyst Ratings BreakdownLatest SURG, NEPH, TELA, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/10/2026SURGSurgePays Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $3.506/4/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/22/2026SURGSurgePays Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/21/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/15/2026SURGSurgePays Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/7/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/5/2026NSPRInspireMD Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $3.005/4/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/21/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)4/21/2026TELATELA Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNEPHNephros$18.79M1.95$0.12 per share28.46$0.96 per share3.51NSPRInspireMD$10.85M2.95N/AN/A$1.83 per share0.37SURGSurgePays$56.96M0.18N/AN/A($0.66) per share-0.63TELATELA Bio$80.28M0.40N/AN/A$0.16 per share4.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNEPHNephros$1.19M$0.0748.15N/AN/A4.06%7.66%5.86%8/6/2026 (Estimated)NSPRInspireMD-$19.92M-$0.73N/AN/AN/A-413.96%-69.42%-57.68%N/ASURGSurgePays-$36.07M-$1.94N/A8.30N/A-64.91%N/A-310.16%8/12/2026 (Estimated)TELATELA Bio-$38.83M-$0.79N/AN/AN/A-49.30%-1,320.81%-55.83%8/10/2026 (Estimated)Latest SURG, NEPH, TELA, and NSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2025SURGSurgePays-$0.19-$0.51-$0.32-$0.51$15.50 million$15.98 million5/12/2026Q1 2026TELATELA Bio-$0.14-$0.21-$0.07-$0.21$18.60 million$19.06 million5/7/2026Q1 2026NEPHNephros$0.01$0.01N/A$0.01$5.02 million$5.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNEPHNephrosN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNEPHNephrosN/A4.553.12NSPRInspireMDN/A6.396.05SURGSurgePaysN/A0.270.26TELATELA Bio8.823.612.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNEPHNephros41.10%NSPRInspireMD44.78%SURGSurgePays6.94%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipNEPHNephros6.70%NSPRInspireMD29.72%SURGSurgePays29.10%TELATELA Bio5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNEPHNephros3010.86 million10.13 millionNot OptionableNSPRInspireMD5046.84 million18.33 millionOptionableSURGSurgePays4025.12 million17.81 millionOptionableTELATELA Bio12044.77 million42.48 millionOptionableSURG, NEPH, TELA, and NSPR HeadlinesRecent News About These CompaniesTELA Bio Healthcare Story Faces New Market ScrutinyMay 15, 2026 | kalkinemedia.comKEarnings Release: Here's Why Analysts Cut Their TELA Bio, Inc. (NASDAQ:TELA) Price Target To US$2.25May 15, 2026 | finance.yahoo.comTELA Bio Inc (TELA) Q1 2026 Earnings Call Highlights: Strong European Growth and Strategic U.S. ...May 13, 2026 | finance.yahoo.comTELA Bio, Inc. (TELA) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comTELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue EstimatesMay 12, 2026 | zacks.comTELA Bio Reports First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comWhat To Expect From TELA Bio Inc (TELA) Q1 2026 EarningsMay 11, 2026 | finance.yahoo.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 | globenewswire.comAxos, Gallagher and TELA Bio post strong growth and strategic movesMay 1, 2026 | msn.comTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports ...April 30, 2026 | markets.businessinsider.comTELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesApril 30, 2026 | globenewswire.comTELA Bio (TELA) Gets a Buy from Canaccord GenuityApril 26, 2026 | theglobeandmail.comTELA Bio to Announce First Quarter 2026 Financial ResultsApril 21, 2026 | globenewswire.comTELA Bio (TELA) price target decreased by 34.78% to 2.30April 10, 2026 | msn.comTELA Bio, Inc. Q4 2025 Earnings Call SummaryMarch 26, 2026 | finance.yahoo.comTELA Bio, Inc.: TELA Bio Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 26, 2026 | finanznachrichten.deTELA Bio (TELA) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | finance.yahoo.comTELA Bio Q4 Earnings Call HighlightsMarch 26, 2026 | defenseworld.netDTELA Bio Analysts Cut Their Forecasts After Q4 ResultsMarch 25, 2026 | benzinga.comTELA Bio, Inc. (NASDAQ:TELA) Q4 2025 Earnings Call TranscriptMarch 25, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingBy Jessica Mitacek | June 4, 2026Broadcom's Whiplash: Shares Tank After Pre-Earnings SurgeBy Leo Miller | June 5, 2026The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in FocusBy Jeffrey Neal Johnson | June 4, 2026Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for InvestorsBy Chris Markoch | June 2, 2026Planet Labs: Coming Back Down to EarthBy Chris Markoch | June 8, 2026SURG, NEPH, TELA, and NSPR Company DescriptionsNephros NASDAQ:NEPH$3.37 -0.20 (-5.60%) Closing price 07/1/2026 03:56 PM EasternExtended Trading$3.56 +0.19 (+5.55%) As of 07/1/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.InspireMD NYSE:NSPR$0.68 -0.02 (-2.51%) Closing price 07/1/2026 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.37%) As of 07/1/2026 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.SurgePays NASDAQ:SURG$0.41 +0.05 (+14.93%) Closing price 07/1/2026 04:00 PM EasternExtended Trading$0.67 +0.25 (+60.52%) As of 07/1/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee.TELA Bio NASDAQ:TELA$0.72 -0.03 (-4.00%) Closing price 07/1/2026 04:00 PM EasternExtended Trading$0.73 +0.01 (+0.97%) As of 07/1/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
